molecules of the month


BD2 domain selective BET inhibitor

oral efficacy in 3 inflammation models

from SBDD of a BD2-selective HTS hit

Science, Mar. 19, 2020

GlaxoSmithKline, Stevenage, UK

Structure of pan-BD2 inhibitor GSK620
1 min read

GSK620 (GlaxoSmithKline (GSK) oral in vivo BD2 domain selective BET inhibitor)

request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.

already a member? log in: